Search Results
Your search for ,itS matches 8694 pages
Showing 1001 - 1050Mutations in 11 Genes May Be Associated With Aggressive Prostate Cancer
Researchers have singled out mutations in 11 genes associated with aggressive types of prostate cancer, according to a novel study published by Darst et al in JAMA Oncology. The new findings may lead to improvements in diagnosis and treatment. Background Currently, oncologists use genetic tests to...
Do Checkpoint Inhibitors Show Benefit in EGFR-Mutated NSCLC After Progression?
In patients with advanced non–small cell lung cancer (NSCLC) harboring EGFR mutations, the role of immune checkpoint inhibitors following disease progression with tyrosine kinase inhibitors has been unclear. Several studies reported at the International Association for the Study of Lung Cancer 2023 ...
High-Intensity Training May Reduce the Risk of Colorectal Cancer in Patients With Lynch Syndrome
Regular and intense aerobic exercise may be effective at reducing the risk of colorectal cancer in patients with Lynch syndrome by improving the immune system's ability to detect and remove potentially harmful cells, according to a novel study published by Deng et al in Clinical Cancer Research....
MD Anderson and Ochsner Health Partner to Create First Fully Integrated Cancer Program in Louisiana
The University of Texas MD Anderson Cancer Center and New Orleans–based Ochsner Health recently announced a partnership to create Ochsner MD Anderson Cancer Center in southeastern Louisiana. Patients with cancer in the region now will have access to treatments that are among the most advanced in...
27th Cancer Leadership Awards Recipients Announced by Friends of Cancer Research
Friends of Cancer Research recently announced its 2023 Cancer Leadership Awards honorees: Commissioner of the U.S. Food and Drug Administration (FDA), Robert Califf, MD, and Congresswoman Debbie Dingell (D-MI). Dr. Califf, recognized for his work in the field of cardiology and the broader medical ...
Catalyzing Change: Young Moroccan Oncologists Spearhead the Fight Against Sarcoma
The management of sarcoma presents several challenges because of its rarity and diverse subtypes, making accurate diagnosis and specialized treatment crucial. A multidisciplinary approach involving various experts from different cancer specialties is the optimal strategy to improve survival and...
Finding a New Life Purpose After Cancer
In the summer of 2012, I was living my dream. At 28 years old, I had gone from an impoverished childhood in South Central Los Angeles to the high life in the city of Los Angeles. Unable to afford to go to college, an after-school program helped launch me into a career in the hospitality industry. I ...
Surgical Oncologist Héber Salvador, MD, PhD, Offers an Inside Look at Cancer Care in Brazil, Complete With Its Diversity and Inequities
In this installment of The ASCO Post’s Global Oncology series, Guest Editor Chandrakanth Are, MBBS, MBA, FRCS, FACS, the Jerald L. & Carolynn J. Varner Professor of Surgical Oncology & Global Health at the University of Nebraska Medical Center, Omaha, spoke with Héber Salvador, MD, PhD,...
ACS Funds UAMS Study to Understand Treatment Resistance in Pancreatic Cancer
Adam Wolfe, MD, PhD, a radiation oncologist at the University of Arkansas for Medical Sciences (UAMS) Winthrop P. Rockefeller Cancer Institute, has received a $583,200 grant from the American Cancer Society (ACS) to study radiation resistance in pancreatic cancer, a lethal disease with the highest...
From Texas to Sweden, Medical Oncologist Gil Morgan, MD, Enjoys Connecting the Cancer Community
In this installment of The ASCO Post’s Living a Full Life series, guest editor Jame Abraham, MD, FACP, spoke with Gil Morgan, MD, a clinical oncologist formerly at the Division of Medical and Radiation Oncology at Skåne University Hospital, Lund, Sweden and now full-time Director of the OncoAlert...
Particulate Matter Concentrations and Incidence of Breast Cancer
Investigators have found that residing in areas with high levels of particulate air pollution may be associated with an increased risk of developing breast cancer, according to a recent study published by White et al in the Journal of the National Cancer Institute. Background Particulate matter...
Lung-MAP Study May Improve Access to Clinical Trials for Underrepresented Patients
The biomarker-driven Lung Cancer Master Protocol (Lung-MAP) may have enrolled a higher percentage of patients who are older, are from rural or socioeconomically deprived areas, and have Medicaid or no insurance compared with conventional, standalone clinical trials in advanced non–small cell lung...
ASCO Participates in President’s Cancer Panel
ASCO joined the President’s Cancer Panel on September 7, 2023, to highlight the numerous ways ASCO is working to advance the National Cancer Plan and achieve President Biden’s Cancer Moonshot goal of “ending cancer as we know it.” This all-day, virtual event was the first public meeting in support...
ASCO Releases Rapid Recommendation Update on Use of Olanzapine to Treat Cancer-Related Cachexia
ASCO recently released a new rapid recommendation update that addresses the use of olanzapine to treat cancer-related cachexia, a topic originally addressed in its 2020 guideline on the management of cancer cachexia in adults with advanced cancer.1,2 At that time, there was insufficient evidence to ...
Highlights in Cancer and Aging From the 2023 ASCO Annual Meeting
The 2023 ASCO Annual Meeting again demonstrated the Society’s commitment to improving cancer care for all older adults. Pertinent questions related to treatment and management in this population were addressed in educational and oral abstract sessions, clinical science symposia, and case-based...
Distributing Scarce Cancer Drugs Legally and Ethically
During the COVID-19 pandemic, many medical specialties became familiar with supply chain interruptions resulting in drug, equipment, and personnel scarcity. Intensive care unit beds, staff, and essential medicines were at times in short supply. The federal government, individual states, and...
Accelerating Progress Against Cancer and Other Life-Threatening Diseases
Cancer—and the quest to accelerate more effective treatments and potential cures for all life-threatening diseases—has perhaps shaped the life of financier Michael Milken more than his legendary career on Wall Street. In the early 1970s, Mr. Milken’s mother-in-law was diagnosed with metastatic...
PSA Screening for HIM Act Introduced in Senate; Aims to Reduce Costs for Prostate Cancer Screening
Bipartisan legislation that may help to eliminate financial barriers to prostate cancer screening was introduced in the U.S. Senate. Sponsored by Senators Cory Booker (D-NJ) and John Boozman (R-AR), the Prostate-Specific Antigen Screening for High-Risk Insured Men (PSA Screening for HIM) Act would...
LungCAN Advocacy Program Nets 25% Increase in LCRP Funding
The Lung Cancer Action Network (LungCAN) advocacy program may have helped increase funding for the U.S. Department of Defense Congressionally Directed Medical Research Program/Lung Cancer Research Program (LCRP) by 25%, according to recent findings presented by Donaldson et al at the International...
Previously Untreated Advanced Melanoma: Addition of Bempegaldesleukin to Nivolumab
In the phase III PIVOT IO 001 trial reported in the Journal of Clinical Oncology, Adi Diab, MD, and colleagues found that the addition of bempegaldesleukin, a pegylated interleukin-2 cytokine prodrug, to nivolumab did not improve treatment outcomes in previously untreated patients with advanced...
ctDNA Identified in Breast Milk From Women With Breast Cancer
Breast milk from women with breast cancer who were diagnosed during pregnancy or postpartum may contain circulating tumor DNA (ctDNA), according to researchers at the Vall d’Hebron Institute of Oncology (VHIO) in Barcelona. The investigators noted that ctDNA can be detected through liquid biopsy in ...
FDA Approves Momelotinib for Patients With Myelofibrosis and Anemia
On September 15, the U.S. Food and Drug Administration (FDA) approved momelotinib (Ojjaara) for the treatment of intermediate- or high-risk myelofibrosis, including primary myelofibrosis or secondary myelofibrosis (post–polycythemia vera and post–essential thrombocythemia), in adults with anemia....
Cancer Moonshot Initiative Receives $240 Million Boost
On September 13, during a meeting of the Cancer Cabinet, President Joe Biden and First Lady Dr. Jill Biden announced a $240 million investment to accelerate advances in cancer-related projects, with the aim of improving treatments and reducing cancer mortality over the next 25 years. The funding,...
Is Adagrasib Active in KRAS G12C–Mutated NSCLC?
The oral KRAS G12C inhibitor adagrasib may offer durable clinical activity, with a median overall survival of 14.1 months and a 2-year survival rate of about 33%, in patients with KRAS G12C–mutated non–small cell lung cancer (NSCLC), according to findings presented by Gadgeel et al at the...
Quarterback Trial: De-escalation of Chemoradiotherapy for Subset of Patients With HPV-Positive Oropharyngeal Cancer
De-escalation of chemoradiotherapy after induction chemotherapy yields excellent oncologic outcomes in patients with high-risk oropharyngeal cancer associated with the human papillomavirus (HPV). Results of the nonrandomized phase II Quarterback trial suggest that this subset of patients may be...
Study Finds Durvalumab Plus Carboplatin and Paclitaxel Effective, Tolerable in Frail Patients With Head and Neck Cancer
As a first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma, the PD-L1 inhibitor durvalumab plus weekly carboplatin and paclitaxel provided clinically significant efficacy in the phase II FRAIL-IMMUNE (GORTEC 2018-03) trial.1 This regimen may prove to be an effective...
CONTINUUM: In Locally Advanced Nasopharyngeal Cancer, Addition of Sintilimab to Chemoradiotherapy Offers Benefit
The addition of the PD-1 inhibitor sintilimab to standard induction chemotherapy and chemoradiotherapy resulted in a significant improvement in 3-year event-free survival, a manageable safety profile, and comparable quality of life in high-risk, locally advanced nasopharyngeal carcinoma vs standard ...
Expert Point of View: Glenn J. Hanna, MD and Sherene Loi, MD, PhD
The ASCO Post asked for comment from Glenn J. Hanna, MD, Director of the Center for Salivary and Rare Head and Neck Cancers, Dana-Farber Cancer Institute, and Assistant Professor of Medicine at Harvard Medical School. Dr. Hanna said it is important to put the findings of KEYNOTE-4121 into context...
Taiwanese Program Shows Potential for Detecting Early-Stage Lung Cancer
Researchers have found that the Taiwan National Lung Cancer Early Detection Program successfully detected 85% of stage 0 and stage I lung cancer cases. The findings by Yang et al were presented at the International Association for the Study of Lung Cancer (IASLC) 2023 World Conference on Lung...
Study Questions Role of Extended Pleurectomy Decortication in Patients With Mesothelioma
Extended pleurectomy decortication combined with chemotherapy was associated with worse survival outcomes, a higher incidence of serious adverse events, and a diminished quality of life in patients with resectable mesothelioma compared with platinum and pemetrexed chemotherapy alone, according to...
NSCLC: Osimertinib Plus Chemo vs Osimertinib Alone
Osimertinib plus chemotherapy may have demonstrated a statistically significant and clinically meaningful progression-free survival benefit in patients with advanced non–small cell lung cancer (NSCLC) compared with osimertinib alone, according to new findings presented by Jänne et al at the...
ASCO Updates Guideline on Assessment, Management of Vulnerabilities in Older Patients Receiving Systemic Cancer Therapy
ASCO has updated a guideline on the practical assessment and management of age-associated vulnerabilities in older patients receiving systemic cancer therapy.1 Among the updates, the guideline adds more detail to domains that should be evaluated in geriatric assessments (GAs) and expands patient...
Perspectives on Cancer Therapy Development
Long ago, as an ethical alternative to military service, I joined the National Cancer Institute’s Yellow Beret Program, and was assigned to its Division of Cancer Treatment (Dr. Vince DeVita) Cancer Therapy Development Branch (Dr. Steve Carter). This program reviewed and rejected or approved all...
Atrium Health Levine Children’s Expands to Include New Outpatient Center for Cancer and Blood Disorders
Atrium Health Levine Children’s is expanding its commitment to deliver oncology, hematology, and cellular therapies care to patients across the region, the United States, and the world with the recent opening of its completely reimagined outpatient center. The Torrey Hemby Center for Cancer and...
Incremental Gains Toward Better Outcomes in Small Cell Lung Cancer
Novel treatments beyond the current chemoimmunotherapies are offering more treatment options in small cell lung cancer (SCLC), though real breakthroughs remain elusive, according to Ticiana Leal, MD, Associate Professor in the Department of Hematology and Medical Oncology, Emory University School...
More on Treatments Under Study in NSCLC From ASCO 2023
Two phase III trials presented at the 2023 ASCO Annual Meeting explored treatments under study for patients with non–small cell lung cancer (NSCLC). In an exploratory analysis of the CodeBreaK 200 trial, the KRAS inhibitor sotorasib was compared with docetaxel chemotherapy in subsets of patients...
Study Shows Benefit With Addition of Tumor Treating Fields Therapy in Metastatic Non–Small Cell Lung Cancer
Tumor treating fields (TTF) therapy in combination with immune checkpoint inhibition improved overall survival in the pretreated, primarily immunotherapy-naive setting in metastatic non–small cell lung cancer (NSCLC), according to findings from the phase III LUNAR study. These results were...
AI-Based Tool Aids in Diagnosis of Cervical Cancers and Precancers
A new artificial intelligence (AI)-based diagnostic tool for colposcopy examinations may improve the accuracy of diagnosing cancerous and precancerous cervical lesions, including cervical intraepithelial neoplasia (CIN), according to a retrospective validation study presented at the 2023 ASCO...
ASCO Remembers Chemotherapy Pioneer and Karnofsky Award Recipient Irwin H. Krakoff, MD
ASCO is saddened by the passing of Irwin H. Krakoff, MD, on August 9, 2023, at the age of 100. He is remembered as one of the founding fathers of modern chemotherapy. Dr. Krakoff was born on July 20, 1923, in Columbus, Ohio. He attended The Ohio State University, earning his bachelor’s degree in...
Rising After Struggle: Surviving My First ASCO Breakthrough in Japan
After a year of hard work preparing a strong abstract for the prestigious 2023 ASCO Annual Meeting, I finally received an acceptance letter from the scientific committee. I was overjoyed to see the efforts of our multinational team being rewarded. A few moments later, I received the decision...
A Near-Future Look at Medicine When AI Has a Mind of Its Own
“Dr. Hope Kestrel was the only person who knew the patient in Room 132 wasn’t responding to the algorithm-selected treatment. She shuffled forward in the hospital security line, wanting to ger her day started already yet dreading how she’d tell her patient the unexpected and devastating news.” So...
New Updated Edition of a Classic in Hematology Literature
Hematologic malignancies make about 10% of all cancer types in the United States, and the multidisciplinary care of these malignancies has evolved rapidly over the past 20 years. In fact, death rates across all blood cancers have been reduced, and once rapidly fatal diseases such as chronic myeloid ...
Benjamin Besse, MD, PhD, Chooses a Career in Medicine Over Music
In this installment of The ASCO Post’s Living a Full Life series, guest editor Jame Abraham, MD, FACP, spoke with Benjamin Besse, MD, PhD, Professor of Medical Oncology at Paris-Saclay University, Orsay, France, and lung cancer specialist at Gustave Roussy Cancer Campus, Villejuif. Currently, Dr....
There’s an App for That: Digital Health Solutions for Treating Insomnia in Cancer Survivors
Guest Editor’s Note: Insomnia is common in patients with cancer and cancer survivors, and it has significant negative consequences. Cognitive behavior therapy for insomnia (CBT-I) is an effective approach for managing insomnia but is not easily available to many patients. In this installment of The ...
Instinct and Perseverance Helped Save Me From Two Cancers
My intuition about my health has served me well over the past 10 years, possibly even saving my life from two serious cancers. In 2013, I was diagnosed with follicular lymphoma. I believe that my awareness of changes in my body led to its early discovery. One evening, after exercising at the gym...
Vivek Subbiah, MD, Joins SCRI to Advance Early-Phase Clinical Research
Sarah Cannon Research Institute (SCRI) recently announced that Vivek Subbiah, MD, has joined the organization as Chief, Early-Phase Drug Development. In his role, Dr. Subbiah will oversee SCRI’s nine drug development units and lead the expansion of early-phase capabilities and programs across the...
Addition of Nivolumab to Stereotactic Ablative Radiotherapy in Early-Stage or Isolated Lung Parenchymal Recurrent NSCLC
In a phase II trial (I-SABR) reported in The Lancet, Joe Y. Chang, MD, of the Department of Radiation Oncology at The University of Texas MD Anderson Cancer Center, Houston, and colleagues found that the addition of immunotherapy with nivolumab to stereotactic ablative radiotherapy (SABR) improved ...
Expert Point of View: Cathy Eng, MD, FACP, FASCO
Cathy Eng, MD, FACP, FASCO, the David H. Johnson Chair in Surgical and Medical Oncology, Professor of Medicine, Hematology and Oncology, Co-Director of GI Oncology and Co-Leader of the Gastrointestinal Cancer Research Program at Vanderbilt-Ingram Cancer Center, Nashville, commented that the...
Expert Point of View: Martina C. Murphy, MD
Discussant of the ENGOT-EN5/GOG-305/SIENDO trial, Martina C. Murphy, MD, Associate Professor of the Department of Medicine, Division of Hematology, University of Florida, shared insights on the topic of maintenance therapy, its effects on quality of life, and toxicity management. Dr. Murphy...
Selinexor Shows Activity as Maintenance Therapy for TP53 Wild-Type Endometrial Cancer in Phase III Trial
Long-term follow-up of selinexor maintenance therapy has demonstrated promising efficacy in patients with TP53 wild-type endometrial cancer, according to data presented during the ASCO Plenary Series: July 2023 Session.1 Selinexor is a selective inhibitor of nuclear export (SINE) approved for use...
